Initial MDA MIDNIGHT™ mission is designed to rendezvous with low Earth orbit space assets to track, counter, capture and de-orbit TORONTO and COLORADO SPRINGS, Colo., April 13, 2026 /CNW/ - MDA Space ...

HyperLight Corporation ("HyperLight"), creator of the TFLN Chiplet(TM) Platform, today announced the availability of 400G-per-lane thin-film lithium niobate (TFLN) photonic integrated circuits (PICs) ...

The MarketWatch News Department was not involved in the creation of this content. TEL AVIV, Israel, Feb. 10, 2026 /PRNewswire/ -- Protai, www.protai.bio, an AI drug discovery startup, announced its ...

Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the ...

This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its Canadian short form base shelf ...

This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated prospectus supplement dated November 18, 2025, to its Canadian short form base shelf ...

(MENAFN- Mid-East Info) The Platform was developed by the UAE Government Leaders Programme and targets a 20 per cent growth in the number of trademarks within its first year of operation Abu Dhabi, ...

If you're looking to trade binary options or forex with flexibility, fast execution, and a high ceiling for payouts, Capitalcore deserves a look. The platform was designed for traders who want more ...

In the Sevilla Platform for Action (SPA), coalitions of countries and stakeholders are announcing 130 high-impact initiatives to implement the Compromiso de Sevilla – the outcome document of the ...

For a limited time, only the first 1,000 users will gain exclusive early access to SocialSafe, securing premium benefits before the platform's full rollout. More than just a backup tool, SocialSafe is ...

A Phase 1 trial of HF50 to evaluate the safety, tolerability, pharmacokinetic characteristics, immunogenicity, and preliminary efficacy in patients with advanced solid tumors is expected to begin in ...